BNTX
SHORT CANDIDATEMeanRevComposite
22.40
Technical
19.50
Fundamental
23.40
Rank
—
Price
86.92
Hurst
0.01
As of
Nov 4, 2026
Daily
BioNTech SE
HealthcareBiotechnologyBioNTech SE is a German biotech company that develops immunotherapies using mRNA technology. The company commercializes the BNT162 vaccine for COVID-19 and maintains an extensive pipeline of experimental cancer treatments in various clinical trial phases, along with investigational vaccines for infectious diseases including influenza, tuberculosis, malaria, and mpox. Founded in 2008 and based in Mainz, the company focuses on advancing precision medicine across oncology and infectious disease areas.
Market cap
$22.1B
P/E (trailing)
—
P/E (forward)
-16.28
PEG ratio
0.05
Dividend yield
0.00%
Beta
1.33
52w range
79.52 – 124.00
Return on equity
-9.30%
Profit margin
-63.64%
Revenue growth
-59.50%
Earnings growth
—
Price history
1Y: 86.92 (-16.4%) · range 83.89–119.34
Cycle position
18/ 100 cycle scoreENTRY ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 72 · GOOD SETUP · exit proximity 0
Conviction
51/ 100 · maturity 57%
VScore.2836
Buildup.2462
EMA entry setup.3072
Fundamentals.1823
Volume profile
POC
92.38
Price vs POC
-5.9%
Overhead supply
96%
Runway
+2.2%
Value area 85.66–98.40 · 96% of 120d volume overhead · heavy supply
Get an AI analyst's read on this ticker.Open the AI analyst
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| earnings-surprise | 0.967 | Nov 4, 2026 |
| financial-news | 0.120 | Nov 3, 2026 |
Pattern & cluster
Pattern
NEUTRALdouble_top:forming
Cluster
NEUTRALForward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -12.78% | +3.05% | mature |
| 40d | -20.26% | +3.05% | mature |